Vitiligo is an autoimmune disease in which depigmented skin results from the destruction of melanocytes 1 , with epidemiological association with other autoimmune diseases 2 . In previous linkage and genome-wide association studies (GWAS1 and GWAS2), we identified 27 vitiligo susceptibility loci in patients of European ancestry. We carried out a third GWAS (GWAS3) in European-ancestry subjects, with augmented GWAS1 and GWAS2 controls, genome-wide imputation, and meta-analysis of all three GWAS, followed by an independent replication. The combined analyses, with 4,680 cases and 39,586 controls, identified 23 new significantly associated loci and 7 suggestive loci. Most encode immune and apoptotic regulators, with some also associated with other autoimmune diseases, as well as several melanocyte regulators. Bioinformatic analyses indicate a predominance of causal regulatory variation, some of which corresponds to expression quantitative trait loci (eQTLs) at these loci. Together, the identified genes provide a framework for the genetic architecture and pathobiology of vitiligo, highlight relationships with other autoimmune diseases and melanoma, and offer potential targets for treatment.
In previous genome-wide linkage and association studies, we identified 27 vitiligo susceptibility loci [3] [4] [5] [6] in European-ancestry subjects, principally encoding immunoregulatory proteins, many of which are associated with other autoimmune diseases 7 . Several other vitiligoassociated genes encode melanocyte components that regulate normal pigmentary variation 8 and in some cases are major vitiligo autoimmune antigens, with an inverse association of variation at these loci with vitiligo versus malignant melanoma 4, 6 . To detect additional vitiligo associations with lower odds ratios, as well as uncommon risk alleles with higher odds ratios (ORs), we conducted a third GWAS (GWAS3) of European-ancestry subjects. We augmented the number of population controls in our previous GWAS1 and GWAS2 studies and performed genome-wide imputation of all three European-ancestry vitiligo GWAS. After quality control procedures, the augmented studies included 1,381 cases and 14,518 controls (GWAS1), 413 cases and 5,209 controls (GWAS2), and 1,059 cases and 17,678 controls (GWAS3), and the corresponding genomic inflation factors were 1.068, 1.059, and 1.013, respectively. We performed a fixed-effects meta-analysis of the three GWAS data sets for 8,966,411 markers (GWAS123; Online Methods). Replication used an additional 1,827 European-ancestry vitiligo cases and 2,181 controls.
Results for the three individual GWAS, the meta-analysis, and the replication study are presented in Fig. 1 , Table 1 , and Supplementary  Table 1 . Twenty-three new loci achieved genome-wide significance (P < 5 × 10 −8 ) for association with vitiligo and demonstrated subsequent replication; of these loci, 21 are completely new (FASLG, PTPRC, PPP4R3B, BCL2L11, FARP2-STK25, UBE2E2, FBXO45-NRROS, PPP3CA, IRF4, SERPINB9, CPVL, NEK6, ARID5B, a multigenic segment that includes BAD, TNFSF11, KAT2A-HSPB9-RAB5C, TNFRSF11A, SCAF1-IRF3-BCL2L12, a multigenic segment that includes ASIP, PTPN1, and IL1RAPL1), while two, CTLA4 and TICAM1, were suggestive in our previous studies. One previously significant locus, CLNK, was no longer significant ( Supplementary  Table 1 ). Another potential new locus, PVT1, exceeded genome-wide significance in the discovery meta-analysis (P = 7.74 × 10 −9 ) but could not be successfully genotyped in the replication study and so remains uncertain. Two other loci, FLI1 and LOC101060498, exceeded genomewide significance in the discovery meta-analysis (P = 3.76 × 10 −8 and P = 3.60 × 10 −11 , respectively) but did not demonstrate replication. Seven additional new loci achieved suggestive significance (P < 1 × 10 −5 ) in the discovery meta-analysis (STAT4, PPARGC1B, C7orf72, PARP12, FADS2, CBFA2T3, and a chromosome 17 locus in the vicinity of AFMID) and gave evidence of replication, but failed to achieve genome-wide significance ( Supplementary Table 1 ).
Together, the most significantly associated variants at the 48 loci ( Table 1) identified by meta-analyses of the three GWAS account for 17.4% of vitiligo heritability (h 2 ~0.75). To assess whether additional independent variants at these loci might account for additional vitiligo heritability, we performed logistic regression conditional on the most significant SNP at each locus. Eight loci (FARP2-STK25, IFIH1, IL2RA, LPP, MC1R, SLA/TG, TYR, and UBASH3A) and the major histocompatibility complex (MHC) region showed evidence of additional independent associations, accounting for an additional 5.1% of vitiligo heritability, for a total of 22.5%. In general, the ORs for the 23 new confirmed loci were lower than those for loci detected previously 6 , 1.15 to 1.27, except for CPVL (OR = 1.84), RALY-EIF252-ASIP-AHCY-ITCH (OR = 1.64), and IL1RAPL1 (OR = 1.77); for these three signals, the minor alleles are uncommon (minor allele frequency (MAF) = 0.03, 0.07, and 0.01, respectively) and thus were not detected in the previous GWAS because of power limitations.
To screen for functional relationships among proteins encoded at the 48 confirmed vitiligo-associated loci, we included all genes under the association peaks at these loci in unsupervised pathway analyses using g:PROFILER 9 , PANTHER 10 , and STRING 11 . PANTHER and g: PROFILER identified an enriched network of BioGRID interactions, most significant for the Gene Ontology (GO) categories immune response, immune system process, positive regulation of response to stimulus, positive regulation of biological process, and regulation of response to stimulus. STRING identified a large potential interaction network (Fig. 2) , with a predominance of proteins involved in immunoregulation, T cell receptor repertoire, apoptosis, antigen processing and presentation, and melanocyte function.
Considering the proteins encoded at the 23 new confirmed vitiligo candidate loci, at least 12 (CTLA4, TICAM1, PTPRC, FARP2, UBE2E2, NRROS, CPVL, ARID5B, PTPN1, TNFSF11, TNFRSF11A, IRF3, and perhaps also IL1RAPL1) have roles in immune regulation, and PPP3CA inactivates FOXP3 and is associated with canine lupus 12 . Six proteins (FASLG, BCL2L11, BCL2L12, SERPINB9, NEK6, and BAD) are regulators of apoptosis, in particular involving immune cells. ASIP is a regulator of melanocyte gene expression, and IRF4 is a key transcription factor for both immune cells and melanocytes.
Several vitiligo-associated genes encode proteins that interact physically and functionally. BCL2L11 and BAD are binding partners that promote apoptosis 13 . CD80 binds to CTLA4 to inhibit T cell activation 14 . BCL2L12 binds to and neutralizes caspase-7 (CASP7) 15 . SERPINB9 binds to and specifically inhibits granzyme B (GZMB) 16 . Eos (IKZF4) binds and is an obligatory co-repressor of FOXP3 in regulatory T cells 17 . RANK (TNFRSF11A) binds to RANKL (TNFSF11) to regulate many aspects of immune cell function, including interaction of T cells and dendritic cells and thymic tolerization 18 . Agouti signaling protein (ASIP) binds to the melanocortin-1 receptor (MC1R) to downregulate production of brown-black eumelanin 19 . IRF4 cooperates with MITF to activate transcription of TYR 20 . The vitiligo-associated HLA-A*02:01:01:01 subtype presents peptide antigens derived from several different melanocyte proteins, including tyrosinase (TYR), OCA2, and MC1R 4,6,21 . Together, these relationships seem to highlight key pathways of vitiligo pathogenesis that are beginning to coalesce.
An unexpected finding from vitiligo GWAS has been an inverse relationship between vitiligo and malignant melanoma risk for genes that encode melanocyte structural and regulatory proteins. TYR, OCA2, and MC1R encode functional components of the melanocyte Figure 1 Genome-wide meta-analysis results. The genome-wide distribution of −log 10 (P values) from the Cochran-Mantel-Haenszel (CMH) metaanalysis for 8,966,411 genotyped and imputed markers from GWAS1, GWAS2, and GWAS3 is shown across the chromosomes. The dashed line corresponds to the threshold for genome-wide significance (P < 5 × 10 −8 ).
l e t t e r s l e t t e r s l e t t e r s and are key vitiligo autoantigens. IRF4 encodes a transcription factor for melanocytes, as well as lymphoid, myeloid, and dendritic cells 22 , whose expression is controlled by alternative tissue-specific enhancers 23 . ASIP and PPARGC1B encode paracrine regulators of melanocyte gene expression. All six loci have important roles in normal pigmentary variation 8, 24 , and for all six the specific alleles associated with vitiligo risk are also associated with protection from melanoma, and vice versa [25] [26] [27] . The inverse genetic relationship of susceptibility to vitiligo versus melanoma suggests that vitiligo may represent enhanced immune surveillance against melanoma 27, 28 , consistent with the threefold reduction in melanoma incidence among patients with vitiligo 29, 30 and the prolonged survival of patients with melanoma who develop vitiligo during immunotherapy 31 . Vitiligo is epidemiologically associated with several other autoimmune diseases, including autoimmune thyroid disease, pernicious anemia, rheumatoid arthritis, adult-onset type 1 diabetes, Addison's disease, and lupus 2, 32 . We searched the National Human Genome Research Institute (NHGRI)-European Bioinformatics Institute (EBI) GWAS catalog and PubMed using the 48 genome-wide significant and 7 suggestive vitiligo susceptibility loci for associations with other autoimmune, inflammatory, and immune-related disorders. Of the 23 new genome-wide significant loci for vitiligo, FASLG has been associated with celiac disease 33 and Crohn's disease 34 ; PTPRC has been associated with ulcerative colitis 35 ; BCL2L11 has been associated with primary sclerosing cholangitis 36 ; CTLA4 has been associated with alopecia areata 37 , rheumatoid arthritis 38 , autoimmune thyroid disease 39, 40 , myasthenia gravis 41 , and type 1 diabetes autoantibody production 42 ; TNFRSF11A has been associated with myasthenia gravis 41 ; and ARID5B has been associated with systemic lupus erythematosus 43 (Fig. 3) . Of the seven suggestive loci, STAT4 has been associated with Behçet's disease 44 , Sjögren's syndrome 45 , and lupus 46 and C7orf72 has been associated with lupus 47 . These concordant associations for vitiligo and other autoimmune and inflammatory diseases add to those involving previously identified vitiligo susceptibility loci, which include RERE, PTPN22, IFIH1, CD80, LPP, BACH2, RNASET2-FGFR1OP-CCR6, TG-SLA, IL2RA, CD44, a chromosome 11q21 gene desert, IKZF4, SH2B3-ATXN2, UBASH3A, and C1QTNF6 (refs. 4,6) . Nevertheless, in most cases, it remains uncertain whether apparent shared locus associations for different autoimmune diseases reflect shared or different underlying causal variants.
A majority of loci associated with complex traits involve causal variants that are regulatory in nature [48] [49] [50] [51] [52] , often corresponding to apparent eQTLs 52 . For TYR 21 , GZMB 53 , and MC1R 7 , principal vitiligo risk derives from missense substitutions, whereas for OCA2 (ref. 6) and MHC class I (ref. 54 ) and class II (ref. 55 ) loci principal vitiligo risk is associated with causal variation in nearby transcriptional regulatory elements. To assess the fraction of vitiligo-associated loci for which causal variation is likely regulatory, we carried out conditional logistic regression analysis of all loci to define independent association signals, and for each signal we compiled all variants that could PPP1R14B   PLCB3  SCAF1  FARP2  TNFRSF11A   SMEK2  PTPN1   BCL2L12  TNFSF11  INSR   PPP3R1  C11orf20  PPP3CA  ESRRA   SRC  SLA  BAD  CASP7   FASLG  TG   BCL2L11  PTPRC  CTLA4  TBK1  BCL2  NLRP1   CD44  GZMB   RALY  CD80  SERPINB9  TICAM1  HLA-A  ASIP  MC1R  HLA-DRB1  IRF3  AHCY  FOXP3  OCA2  TYR  FOXP1  HERC2  PTPN22  IKZF4  ITCH  IFIH1  IL2RA  UBE2E2   SH2B3  ATXN2 UBASH3A RNASET2 IRF4 C1QTNF6 BACH2 Figure 2 Bioinformatic functional interaction network analysis of the proteins encoded by all positional candidate genes at all confirmed and suggestive vitiligo candidate loci. As a first step, unsupervised functional interaction network analysis was carried out using STRING v10.0 (ref. 11), considering each protein as a node and permitting ≤5 s-order interactions to maximize connectivity. Nodes that shared no edges with other nodes were then excluded from the network. Edge colors are from STRING: teal, interactions from curated databases; purple, experimentally determined interactions; green, gene neighborhood; blue, databases; red, gene fusions; dark blue, gene co-occurrence; pale green, text-mining; black, coexpression; lavender, protein homology. Note that SMEK2 is an alternative name for PPP4R3B. l e t t e r s not be statistically distinguished. All the variants were then annotated against all available Encyclopedia of DNA Elements (ENCODE) data sets for immune-related and melanocyte-related cells ( Supplementary  Table 2 ). Overall, at approximately 58% of loci, the most significant variants (or statistically indistinguishable variants) were within a transcriptional regulatory element predicted by ENCODE data 56, 57 .
Only about 15% were in coding regions, with several resulting in missense substitutions. To further assess the general functional categories of apparent causal variants for vitiligo, we applied stratified LD score regression 51 to the GWAS meta-analysis summary statistics. The greatest enrichment of heritability was observed for markers in regulatory functional categories, with considerably less enrichment for markers in protein-coding regions (Fig. 4) . We used two approaches to assess the correspondence of vitiligo association signals with expression of genes in the vicinity. We used PrediXcan 58 to predict the expression of 11,553 genes in whole blood for each study subject and then tested association of predicted expression for each gene with vitiligo status. We used a Bayesian method to assess the colocalization of cis-eQTL signals in purified blood monocytes with the confirmed vitiligo association signals. The PrediXcan analysis found 83 genes for which significant differential expression was predicted in vitiligo cases versus controls after Bonferroni correction ( Supplementary Table 3 ); of these, 75 were located within 1 Mb of one of the 48 confirmed vitiligo susceptibility loci, demonstrating highly significant enrichment (P < 0.00001) in comparison with the locations of genes that were not significant in PrediXcan analysis. The eQTL analysis found that eight of the confirmed vitiligo association signals showed significant (PP 3 + PP 4 > 0.99 and PP 4 /PP 3 > 5; Online Methods) colocalization with eQTL association signals identified in purified monocytes ( Supplementary Fig. 1 and Supplementary Table 4 ). Of the confirmed vitiligo-associated genes that could be tested using both methods, six were significant in both analyses (CASP7, HERC2-OCA2, ZC3H7B-TEF, TICAM1, RERE, and RNASET2-FGFR1OP-CCR6). For all of these genes except CASP7, one or more of the most associated SNPs not distinguishable by logistic regression were located within or very close to an ENCODE element likely to regulate gene expression in immune cell types, melanocytes, or both ( Supplementary Table 2 ).
Like a jigsaw puzzle, the pieces of the vitiligo pathogenome are thus beginning to fit together, revealing a complex network of immunoregulatory proteins, apoptotic regulators, and melanocyte components that mediate both autoimmune targeting of melanocytes in vitiligo and susceptibility to melanoma. For vitiligo, as for other complex diseases, there is enrichment of causal variation in regions that regulate gene expression. This may bode well for identifying potential therapeutic targets, as pharmacological modulation of dysregulated biological pathways may prove more tractable than attempts to target proteins affected by amino acid substitutions. Combined CMH GWAS123 summary statistics were analyzed using the stratified LD score regression method with the full baseline model 51 .
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The annotations are colored by category: yellow, regulatory; blue, protein coding; green, intronic. Bar height represents enrichment, which is defined as the estimated proportion of heritability explained by the category divided by the proportion of SNPs in the category. Error bars represent jackknife standard error for the enrichment values. For each category, the percentage of the total markers in the category is given in parentheses. The dashed line represents a ratio of 1 (no enrichment). An asterisk indicates enrichment significant at P < 0.05 after Bonferroni correction for the 20 categories tested (the categories 'conserved', 'repressed', 'transcribed', and 'promoter flanking' were removed and considered insufficiently specific). CTCF, CCCTC-binding factor; DGF, digital genomic footprint; DHS, DNase hypersensitivity site; TFBS, transcription factor binding site; TSS, transcriptional start site. H3K4me1, H3K4me3, H3K9ac, and H3K27ac are regulatory chromatin marks 56, 57 .
